HC Wainwright reiterated a “buy” rating and set a $63.00 target price on shares of Arcturus Therapeutics in a research note on Friday, February 14th. BTIG Research initiated coverage on shares ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback